Plain-English translation of NCT05694312 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether ibrutinib, a targeted medication, can treat autoimmune hemolytic anemia (a condition where your immune system mistakenly destroys your red blood cells) in people who also have chronic lymphocytic leukemia, small lymphocytic lymphoma, or a related blood condition. Researchers want to see if this medication can help patients whose anemia has not responded well to steroid treatments or keeps coming back.
Many patients with these blood cancers develop autoimmune hemolytic anemia that doesn't respond well to standard treatments like steroids or rituximab. This trial exists to find out whether this medication, which works differently than current options, might offer help to patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You would take ibrutinib by mouth once daily at 420 mg for up to 12 cycles, with each cycle lasting 28 days (roughly 12 months total). During treatment, you'll have regular blood tests and clinic visits to check how well the medication is working and watch for side effects. After you finish taking the medication, researchers will follow up with you for one more year to see how you're doing.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Italy
Phase
Testing effectiveness
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Enrollment target
~45 participants
Started
November 2023
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Paola Fazi
Gruppo Italiano Malattie EMatologiche dell'Adulto
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.